INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 217S · 10 late217 trades$54.77M
  2. 02SPSaba Capital Management, L.P.58B / 21S · 3 late79 trades$24.55M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04CFCheng Chi Fung0B / 42S42 trades$15.33M
  5. 05RARothblatt Martine A0B / 33S33 trades$5.50M
  6. 06RJRubinstein Julie0B / 32S32 trades$5.55M
  7. 07LBLeach Bryan0B / 30S30 trades$7.97M
  8. 08AOAtay Oguzhan0B / 30S30 trades$7.55M
  9. 09JDJenkins William D Jr0B / 30S30 trades$13.38M
  10. 10BSBiswas Sanjit0B / 28S28 trades$22.33M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  3. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  4. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  5. SELLIBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
  6. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
  7. BUYBBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K
  8. SELLBCYCBICYCLE THERAPEUTICS PLCOct 2 – Oct 56 insiders$63K

Form 4 transactions

65,929 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
MA
Merriman Dwight ADirector
MDBMongoDB, Inc.
Open-market sale · 10b5-1 plan
SELL$1.70M
4,846 sh
Nov 2, 2026Nov 4, 2026
Page 60 of 1649
← PrevNext →
traded Nov 2, 2026
+2d
SEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
ZP
Zornio PeterChief Technology Officer
EMREMERSON ELECTRIC CO
Tax withholding
F$124K
745 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
BC
Barlow CarroleeDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
10.2K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
250.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
7,905 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
19.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
7,365 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
205.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
7,296 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DP
DeLucchi Graziano Angelo Giovanni PasquinoDirector
USGOU.S. GoldMining Inc.
Grant or award
A$57K
10.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
200.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
60.4K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,750 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
TM
Tang MichaelSr VP, Secy & Chf Leg Ofc
EMREMERSON ELECTRIC CO
Tax withholding
F$179K
1,073 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
HA
Hovnanian Alexander A.President
HOVHOVNANIAN ENTERPRISES INC
Tax withholding
F$81K
770 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BC
Barlow CarroleeDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,293 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
13.5K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,293 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
30.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
18.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
250.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,847 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
300.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
FL
Flavin LisaSenior VP & CCO
EMREMERSON ELECTRIC CO
Tax withholding
F$125K
750 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
18.6K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
SL
Sorsby J LarryDirector
HOVHOVNANIAN ENTERPRISES INC
Tax withholding
F$193K
1,842 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
280.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BC
Barlow CarroleeDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,989 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
WC
Woods Todd CharlesChief Commercial Officer
WAYWaystar Holding Corp.
Tax withholding
F$111K
4,042 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
17.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
70.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
CJ
Comly Barbara J.EVP, GC & Corporate Secretary
MIAXMIAMI INTERNATIONAL HOLDINGS, INC.
Open-market sale · 10b5-1 plan
SELL$819K
23.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
TD
Tsao DavidDirector, Chief Technology Officer
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
208 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BC
Barlow CarroleeDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
12.4K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
22.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence